Bacil Pharma Ltd Stock Price Today (NSE: BACPHAR)
Fundamental Score
Bacil Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bacil Pharma Ltd share price today is ₹39.10, down 3.27% on NSE/BSE as of 17 June 2026. Bacil Pharma Ltd (BACPHAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹59.78 (Cr). The 52-week high for BACPHAR share price is ₹61.80 and the 52-week low is ₹26.69. At a P/E ratio of 93.40x, BACPHAR is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -0.98% and a debt-to-equity ratio of 0.00.
Bacil Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Bacil Pharma Ltd share price chart: -4.16% return over the past month. 52-week high ₹61.80, 52-week low ₹26.69.
Bacil Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹52.80 | ₹52.80 | ₹48.01 | ₹48.75 | 926.00 (Cr) | |
| ₹50.50 | ₹52.51 | ₹49.77 | ₹50.32 | 6.64K (Cr) | |
| ₹52.11 | ₹52.11 | ₹49.00 | ₹50.03 | 3.37K (Cr) | |
| ₹51.81 | ₹53.20 | ₹49.50 | ₹51.09 | 10.31K (Cr) | |
| ₹52.95 | ₹53.00 | ₹50.79 | ₹50.79 | 4.18K (Cr) | |
| ₹54.69 | ₹54.69 | ₹50.70 | ₹53.46 | 586.00 (Cr) | |
| ₹53.78 | ₹53.88 | ₹51.31 | ₹52.18 | 12.96K (Cr) | |
| ₹57.00 | ₹57.00 | ₹52.00 | ₹53.78 | 11.33K (Cr) | |
| ₹53.49 | ₹54.84 | ₹51.16 | ₹54.56 | 14.14K (Cr) | |
| ₹51.43 | ₹56.81 | ₹51.41 | ₹52.24 | 8.44K (Cr) |
Bacil Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹50.50 | ₹52.80 | ₹48.01 | ₹48.75 | -3.47% | |
| ₹54.12 | ₹59.90 | ₹49.00 | ₹50.03 | -7.56% | |
| ₹47.73 | ₹61.80 | ₹45.42 | ₹56.95 | +19.32% | |
| ₹47.38 | ₹51.90 | ₹43.71 | ₹47.73 | +0.74% | |
| ₹39.48 | ₹51.46 | ₹35.06 | ₹48.35 | +22.47% | |
| ₹37.42 | ₹46.90 | ₹36.12 | ₹39.70 | +6.09% | |
| ₹40.20 | ₹43.69 | ₹32.52 | ₹35.64 | -11.34% | |
| ₹32.83 | ₹42.00 | ₹26.69 | ₹40.09 | +22.11% | |
| ₹43.65 | ₹47.90 | ₹34.55 | ₹34.55 | -20.85% | |
| ₹35.06 | ₹43.70 | ₹31.59 | ₹42.87 | +22.28% | |
| ₹37.58 | ₹37.58 | ₹35.63 | ₹36.90 | -1.81% | |
| ₹34.01 | ₹37.58 | ₹34.01 | ₹37.58 | +10.50% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Bacil Pharma is a micro-cap lottery ticket with a high chance of ending up worthless.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The exchange sought clarification from Bacil Pharma on February 24, 2026, regarding significant price movement, but a reply is still awaited. The company reported a standalone net profit of in the December 2025 quarter.
CORE STORY (THE REAL GAME)
Bacil Pharma is a micro-cap play in the Indian pharmaceuticals sector, attempting to capitalize on generic drug manufacturing and distribution. The real game is survival and potential turnaround, not dominance.
- Recent price volatility with no clear fundamental reason
- Indian pharma sector growth potential
- Micro-cap stocks can experience rapid growth from a low base
- Significant order wins
- Strategic partnerships
- Tangible improvement in financial performance
- Micro/SME cap implies high liquidity risk
- Negative ROE and ROCE
- Minimal promoter holding
Promoter holding decreased by 0.12%. No FII or DII interest.
Indian pharma sector is projected to grow to $130 billion by 2030.
No - Free Cash Flow 5Y: ₹-4.16 Cr
If Bacil Pharma can demonstrate consistent profitability and secure significant orders, the outlook could improve. However, current financials suggest a high risk of failure.
Primary Thesis Risk
Lack of profitability and minimal promoter holding make this a high-risk investment.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Bacil Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bacil Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BACPHAR across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-0.98%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.97%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 93.40x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-97.92%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (2.13% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-4.16 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.08%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Bacil Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Bacil Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Bacil Pharma LtdBacil Pharma Lt...Selected✓ BACPHAR • 524516 | 0.1/100 | ₹39.10₹39 | ₹59.78₹59.78 | 93.40Average 93.4 Average | -0.98%Poor -0.98% Poor | -0.97%Poor -0.97% Poor | 0.00Excellent 0.0 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Bacil Pharma Ltd Quarterly Performance
Latest quarterly metrics for BACPHAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-97.92%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Bacil Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BACPHAR — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Bacil Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Bacil Pharma Ltd (BACPHAR) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Bacil Pharma Ltd
About BACPHAR (Bacil Pharma Ltd)
Bacil Pharma Ltd is a dynamic pharmaceutical company rooted in the bustling metropolis of Mumbai, India. Established in 1987, BACPHAR has steadily grown into a significant player i...n the Indian pharmaceutical landscape. With a keen focus on meeting the diverse healthcare needs of the nation, they are dedicated to providing high-quality, affordable medicines to improve the lives of people across the country. Driven by a commitment to scientific innovation and ethical business practices, the company operates with a strong sense of social responsibility, ensuring that its products are accessible to all segments of society. They are steadfast in their mission to contribute meaningfully to the healthcare ecosystem in India. BACPHAR's comprehensive product portfolio encompasses a wide range of therapeutic areas, catering to various medical conditions. From commonly prescribed tablets and convenient capsules to specialized injectables and soothing ointments, they offer a solution for many healthcare requirements. The company takes immense pride in adhering to stringent quality control measures at every stage of the production process, from sourcing the finest raw materials to employing cutting-edge manufacturing techniques. This commitment to excellence ensures that each medicine that bears the BACPHAR name is safe, effective, and of the highest possible standard. Their dedication to quality has earned them the trust and confidence of healthcare professionals and patients alike. Strategically headquartered in Mumbai, a hub of pharmaceutical activity, BACPHAR benefits from its proximity to key industry resources and talent. This advantageous location enables them to stay at the forefront of pharmaceutical advancements and maintain a competitive edge in the market. Their extensive distribution network spans across India, ensuring that their products reach even the most remote areas of the country. BACPHAR is committed to continuous improvement, constantly investing in research and development to expand its product offerings and adapt to the evolving needs of the healthcare industry. The company remains focused on sustainable growth and creating lasting value for its stakeholders.
Company Details
Key Leadership
BACPHAR Share Price: Frequently Asked Questions
What is the current share price of Bacil Pharma Ltd?
Bacil Pharma Ltd (BACPHAR) trades at ₹39.10 on NSE and BSE. Market cap ₹59.78 (Cr). Educational data only.
What is the P/E ratio of Bacil Pharma Ltd?
Bacil Pharma Ltd has a P/E of 93.40x vs industry average 31.77x.
What is the Bull Run score for Bacil Pharma Ltd?
Bacil Pharma Ltd has a Bull Run score of 0.1/100 based on 25+ financial parameters.
Does Bacil Pharma Ltd pay dividends?
Bacil Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Bacil Pharma Ltd?
Bacil Pharma Ltd has ROE of -0.98%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Bacil Pharma Ltd?
Bacil Pharma Ltd has debt-to-equity of 0.00.
Is Bacil Pharma Ltd a good investment?
Bull Run gives Bacil Pharma Ltd a score of 0.1/100. This is not investment advice — consult a SEBI-registered advisor.